A New PosSuccessful Collaboration between Recipharm OT Chemistry and Oncopeptides AB in the Development of Melflufen, a Peptidase-Potentiated Alkylating Agent in Clinical Trialster Abstract

Programme : Back to Marie Wiik

Poster

127

A New PosSuccessful Collaboration between Recipharm OT Chemistry and Oncopeptides AB in the Development of Melflufen, a Peptidase-Potentiated Alkylating Agent in Clinical Trialster Abstract

Authors

M Wiik²; M Bouma¹;
¹ Recipharm, Sweden; ² Recipharm AB, Sweden

Abstract

Despite recent advances in therapy, multiple myeloma (MM) remains
incurable, showing the need for novel therapies.

Melflufen is a lipophilic peptide-conjugated alkylator that rapidly
delivers a highly cytotoxic payload into myeloma cells through peptidase
activity.

Melflufen is currently under evaluation in phase III study for the
treatment of multiple myeloma.

The poster describes the development of
Melflufen from early pre-clinical discovery to the currently on-going clinical
trials.

Next Poster - Poster 128

Programme

Hosted By

ELRIG

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis